Joanna Tyzack, MD
Endocrinology, Diabetes & Metabolism · Timonium, MDNPI 1487659892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations.
Across 347 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$759
- AbbVie$472
- Novo Nordisk$468
- AstraZeneca$347
- Sanofi-aventis U.S. LLC$337
- Radius Health, Inc.$314
- plus $5K from 47 others
What the payments were for
- Food & beverage$7,20399%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,263 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $133,255 |
| JardianceEmpagliflozin | 57 | $81,601 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $50,878 |
| MounjaroTirzepatide | 29 | $36,399 |
| TrulicityDulaglutide | 15 | $34,776 |
| SynthroidLevothyroxine Sodium | 318 | $34,409 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $30,042 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $29,777 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $21,159 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $20,828 |
| JanuviaSitagliptin Phosphate | 13 | $16,254 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $15,752 |
| Novolog FlexpenInsulin Aspart | 32 | $11,382 |
| HumalogInsulin Lispro | 27 | $10,444 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $468 | $142,59993 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $277 | $81,61971 claims |
| Boehringer IngelheimJardiance | $233 | $81,60157 claims |
| AbbVieSynthroid | $472 | $34,409318 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $337 | $20,82814 claims |
| MerckJanuvia | $13 | $16,25413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $161 | $4,601337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Timonium
- Jeffrey MindelTimonium$7K
- Ruth HorowitzTimonium$7K
- Ashley DavidsonTimonium$6K
- Meena KhanTimonium$5K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.